Health Economics Summer School 2022

Carl Bosch Auditorium (Heidelberg, Studio Villa Bosch)

Carl Bosch Auditorium

Heidelberg, Studio Villa Bosch

Schloß-Wolfsbrunnenweg 33 69118 Heidelberg Germany
Michael Schlander (Deutsches Krebsforschungszentrum)

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) Division of Health Economics and the University of Heidelberg are delighted to invite you to the Heidelberg Health Economics Summer School 2022.

A major branch of health economics is concerned with the study of how scarce healthcare resources are allocated among competing healthcare programs and, by implication, among different groups in society. In health economics, tools such as cost-effectiveness analysis (CEA) are often used to inform decision makers. Conventionally, CEA is designed to help achieve the maximum potential health benefits given a resource constraint or "scarcity". Results from conventional CEAs may, however, contradict prevailing social norms and preferences. The Summer School addresses the underlying issues by introducing and reviewing concepts and methods divided into two modules: basic and advanced. Together, these two modules offer a comprehensive overview of principles and methods, but they may also be attended separately.

The Basic Module of the Summer School introduces basic concepts of health economics and addresses practical issues faced by health care decision makers responsible for allocating scarce resources. One of the main objectives of the Summer School is to bring together different stakeholders, such as payers, physicians, policy makers, representatives from the industry and academia, and others who are involved in different segments of the health care system. Therefore, the Basic Module was created with the objective of giving those without previous knowledge of health economics the tools to comprehend key issues.

The highly interactive program will use exercises and case studies, designed to address the search for “value for money” in the context of (health) economic evaluations and Health Technology Assessments (HTAs) in theory and practice.

After the first two days, participants should be able to:

  • identify the key elements relevant the organization of health care systems (e.g., provision and funding);
  • understand and describe the principles of economic analysis in health care;
  • be familiarized with the concepts related to the identification, measurement, valuation and analysis of health-outcomes and costs;
  • recognize the health economics techniques used to inform resource allocation and priority setting in the health system;
  • appreciate the role of economic evaluation in health care
  • identify the key elements relevant for the organization of health care systems (e.g. provision and funding)

Prof. Michael Schlander, DKFZ & University of Heidelberg, Germany.

Dr. Diego Hernández Carreno, DKFZ. Heidelberg, Germany.

Dr. Karla Hernández-Villafuerte, DKFZ. Heidelberg, Germany.


Participants may also enroll for this module as a stand-alone subject.


The Advanced Module includes an in-depth review of the strengths and limitations of the conventional approaches to economic evaluations, where both participants and speakers of various backgrounds will discuss implications, potential solutions, and ways forward.

With this in mind, Module B will address the strengths, weaknesses, limitations, and – on this basis – the appropriate use of health economic evaluation methods, ranging from cost benefit analysis (CBA) and cost utility / effectiveness analysis (CUA/CEA) to more recently advocated multi-criteria decision analysis (MCDA) or social cost value analysis (SCVA). Arguments against and in favour of alternative approaches and concepts that capture citizens’ social norms and preferences will be discussed from different points of views: the private sector, the academic sector, and policy makers. Potential implications for cost value assessments of (ultra) orphan medicinal products, cancer and end-of-life treatments, as well as “personalized medicine” will be addressed by a group of international experts in Health Technology Assessment (HTA), evidence-based medicine, health economics, and medical ethics.

The program is based on presentations and panel discussions, in which questions and commentary from participants is strongly encouraged.

After the last three days, participants should be able to:

  • understand the background behind the assumptions refering to the utilities values used in conventional economic evaluation;
  • be familiar with the most recent advocated proposals addressing the limitations of the conventional approach, such as multi-criteria decision analysis (MCDA) and social cost value analysis (SCVA);
  • be aware of the challenges of capturing social preferences and reflecting these preferences on the allocation of healthcare resources;  
  • appreciate the arguments presented by different stakeholders in favour of and against the conventional approaches, as well as the most recent proposed methodologies;
  • understand and be part of the discussion on the ways in which economic evaluation can be brought forward, addressing the current challenges of the health sector, and such that future evaluations will be able of adequately inform allocation of healthcare resources 


Prof. Amiram Gafni, Centre for Health Economics and Policy Analysis, McMaster University. Hamilton, ON, Canada. To Be Confirmed

Josie Godfrey, Director, JG Zebra Consulting. London, UK. Formerly Associate Director - Highly Specialised Technologies at the National Institute for Health and Care Excellence (NICE). To be confirmed

Prof. Søren Holm, University of Manchester, UK & University of Oslo, Norway. To be confirmed

Dr. Mohit Jain, Vice President Market Access, BioMarin. London, UK. To be confirmed

Prof. Frank R. Lichtenberg, Columbia Business School. New York, NY, USA. To be confirmed

Prof. Jorge Mestre-Ferrandiz, Universidad Carlos III. Madrid, Spain. To be confirmed

Prof. Ulf Persson, The Swedish Institute for Health Economics. Stockholm, Lund, Sweden. To be confirmed

Prof. Maarten Postma, University of Groningen. Groningen, The Netherlands. To be confirmed

Prof. Gérard de Pouvourville, ESSEC - École Supérieure des Sciences Économiques et Commerciale. Paris, France. To be confirmed

Prof. Jeffrey Richardson, Monash University. Melbourne, Vic, Australia. To be confirmed

Prof. James Robinson, University of California at the Berkeley Center for Health Technology. Berkeley, CA, USA. To be confirmed

Prof. Michael Schlander, DKFZ & University of Heidelberg. Heidelberg, Germany. Confirmed for 2022

Prof. Adrian Towse, The Office of Health Economics. London, UK. To be confirmed


Participants may also enroll for this module as a stand-alone subject.




  • Monday, 5 September
    • 10:00 10:30
      Welcome Reception and Registration 30m
    • 10:30 11:00
      Module A: Introduction to Program & Objectives
    • 11:00 12:30
      Module A: International Health Care Systems: Organization, Financing, Performance
    • 12:30 13:30
      Lunch Break 1h
    • 13:30 14:45
      Module A: Fundamentals of Health Economics: Economics as a Way of Thinking
    • 14:45 16:15
      Module A: Group Exercise
    • 16:15 16:45
      Coffee Break 30m
    • 16:45 18:00
      Module A: Value and Valuation in Health Economics
    • 18:00 19:30
      Module A: Group Exercise
    • 20:00 21:00
      Networking activity: Guided walk to Heidelberg Castle and Old Town 1h
  • Tuesday, 6 September
    • 09:00 09:30
      Module A: Summary of Day 1: What Have We Learnt on Day 1?
    • 09:30 10:45
      Module A: Costing in Theory & Practice
    • 10:45 11:15
      Coffee Break 30m
    • 11:15 12:45
      Module A: Group Exercise
    • 12:45 13:45
      Lunch Break 1h
    • 13:45 14:45
      Module A: Cost Benefit Analysis in Practice
    • 14:45 16:00
      Module A: Group Exercise
    • 16:00 16:30
      Coffee Break 30m
    • 16:30 17:45
      Module A: Decision making in healthcare. The role of Health Technology Assessment (HTA)
    • 17:45 19:00
      Module A: Economic evaluation and HTA